The majority of acetylcholine receptors (AChRs) at normally innervated neuromuscular junctions are stable, with a halflife averaging about 12 d in most rodent muscles. Following denervation, the AChRs turn over much more rapidly after a lag period. The mechanism by which motor nerves normally maintain stabilization of junctional AChRs is not yet known. In order to determine whether synaptic transmission plays a role in this process, we have compared the effects of preand postsynaptic chloinergic blockade with those of surgical denervation.
'251-a-bungarotoxin was used to label junctional AChRs and follow their loss over time. Presynaptic blockade of quanta1 ACh transmission was produced in the soleus (SOL) and flexor digitorum brevis muscles of mice by repeated injections of type A botulinum toxin. Postsynaptic blockade of quanta1 and nonquantal ACh transmission was produced by continuous infusion of a-bungarotoxin in the SOL. Our findings show that treatment with botulinum toxin resulted in an accelerated loss of junctional AChRs that was similar to the effects of surgical denervation, though briefly delayed in its onset. Treatment with a-bungarotoxin produced an effect that was quantitatively equivalent to the accelerated loss of junctional AChRs following surgical denervation, with an identical time course. These results support the concept that cholinergic synaptic transmission is a mediator of the neural control of stability of junctional AChRs. The possibility that receptor stabilization may represent a mechanism of long-term postsynaptic "memory" dependent on neural transmission is discussed.
Both the distribution and the turnover ofacetylcholine receptors (AChRs) of mammalian skeletal muscles arc rcgulatcd to a large extent by motor nerves (Fambrough, 1979 : Drachman et al.. 1984 Salpctcr and Loring, 1985; Schuetze and Role, 1987) . In normally innervated mature muscles, AChRs are present almost exclusively at the postsynaptic membranes of neuromuscular junctions (Milcdi, 1960; Albuquerque et al., 1974; Bevan and Steinbach, 1977; Fambrough, 1979; Salpeter, 1987) . The majority of junctional AChRs are stable; their half-lives are reported to range from 8 to 13 d in rodents (Berg and Hall, 1975b; Loring and Salpeter, 1980; Bevan and Steinbach. 1983; Stanley and Drachman, 1983~) . There is a growing body of evidence that the stability of these junctional AChRs depends on some function of the motor nerve.
(1) Following surgical denervation, the rate of degradation of preexisting stable AChRs accclcrates markedly after a lag period of several days, attaining a half-life of 2-5.6 d (Loring and Salpcter, 1980: Levitt and Salpeter, 198 I ; Stanley and Drachman, 1981; Bcvan and Steinbach, 1983) . (2) After reinnervation of the denervatcd muscle, the AChRs are again stabilized (Salpeter et al., 1986) . (3) Recently we have found that the initial stabilization of new AChRs after insertion at normal mature neuromuscular junctions also requites inncrvation (Stanley and Drachman. 1983a.c; D. Ramsay and D. B. Drachman, unpublished observations) . Taken together, thisevidence indicates that the motor nerve provides some influence that results in stabilization of junctional AChRs and maintcnance of their stability. The mechanism by which the nerve's receptor-stabilizing influence is mediated is not yet known. Since cholincrgic synaptic transmission has been shown to play a role in the neural rcgulation of other properties of skeletal muscles, including the synthesis and insertion of cxtrajunctional AChRs, and the resting membrane potential (Thesleff, 1960; Berg and Hall, I975a: Pcstronk et al., 1976; Mathers and Thesleff. 1978; Rubin et al., 1980; Drachman et al., 1982) we wondered ifACh transmission might also influence the stability of junctional AChRs. Other hypothetical possibilities include physical contact bctwcen nerve and muscle membranes (Steinbach, 1974; Anderson and Cohen, 1977; McMahan et al., 1984) or nontransmitter substances released by the nerve (Albuquerque et al., 1972; Cangiano, 1973) . In the present study, we have examined the role of ACh transmission in the maintenance of stability ofjunctional AChRs in 2 muscles of the mouse, the soleus (SOL) and the flexor digitorum brcvis (FDB). These 2 muscles were used because their junctional AChRs have different rates of turnover and different time courses of denervation-induced destabilization. We studied the change in turnover of preexisting junctional AChRs following pharmacologic blockade ofcholinergic neuromuscular transmission. To do this we used 2 specific neurotoxins, botulinum toxin and a-bungarotoxin (cu-BuTx). Uotulinum toxin selectively blocks the quanta1 release of ACh from motor nerve terminals, whereas n-BuTx blocks AChRs postsynaptically, thereby interrupting both quanta1 and nonquantal ACh transmission (Brooks, 1956; Thesleff. 1960; Changeux et al., 1970; Miledi and Potter, 1971; Lee, 1972 : Kao et al., 1976 .
Our findings show that treatment with botulinum toxin resulted in an accelerated loss of stable AChRs that was similar to the effect of surgical denervation, though delayed in its onset. Treatment with tu-BuTx quantitatively reproduced the effect of The Journal of Neuroscience, August 1989 , 9(8) 2903 surgical denervation, with an identical time course. These results support the concept that cholinergic synaptic transmission plays an important role in mediating the neural control of turnover of stable junctional AChRs. The implication that similar mechanisms of transmitter-driven receptor stabilization may contribute to synaptic "memory" is discussed.
Materials and Methods
Experimental design. In order to compare the effects of pharmacologic blockade of neuromuscular transmission and denervation on the stability ofjunctional AChRs, we studied the turnover ofjunctional AChRs by monitoring the loss over time of 'z'l-a-BuTx that was specifically bound to junctional AChRs in viva. The loss of bound 'z'I-a-BuTx has been widely used to follow the loss of AChRs in skeletal muscles (Berg and Hall, 1975b; Devreotes and Fambrough, 1975; Merlie et al., 1976; Bevan and Steinbach, 1977; Gardner and Fambrough, 1979; Loring and Salpeter, 1980; Drachman, 1983c, 1987; Salpeter et al.. 1986; Ramsay ct al., 1988) .
In each series of experiments, we first prepared a pure population of labeled stable junctional AChRs, as described below. We then measured (I) the turnover of "control" stable junctional AChRs (i.e., without pharmacologic treatment or denervation); (2) the effect of surgical dencrvation on the turnover of junctional AChRs; (3) the effect of trcatment with botulinum toxin or a-BuTx on the turnover of junctional AChRs. WC were thus able to compare the effects of denervation and pre-and postsynaptic pharmacologic blockade of ACh transmission on the loss of stable junctional AChRs.
Female Swiss mice were used throughout these experiments: the animals were anesthetized with chloral hydrate (0.5 gm/kg body weight) and ether for all procedures.
Labeling of AChRs with "'I-U-BuTx. AChRs of SOL muscles wcrc labeled by injecting "'I-cu-BuTx (0.04 &gm body weight in IO ~1 PBS) under direct visualization. In the experiment on the FDB muscles, injections were made percutaneously into the sole of the right foot (0.5 pg "'I-u-BuTx in 20 ~1 PBS). All injections were made via a fine 30 gauge needle.
Preparation of muscles with pure populations of labeled stable AChRs. We have previously found that neuromuscular junctions normally contain 2 populations of AChRs: a subpopulation of rapidly turned over receptors (RTOs) with a half-life of approximately I d and a majority of stable receptors with a half-life averaging I2 d. In order to follow the turnover of a pure population of stable receptors, we waited 6 d after labeling the junctional AChRs, so as to allow virtually all the RTOs to be degraded Drachman, 1983c, 1987; Ramsay et al., 1988) . At this time point (designated day 0), the only remaining labeled AChRs are the stable ones.
Surgicaldenervation. The SOL and FDB muscles were denervated on day 0 by sectioning the sciatic nerve in the midthigh and avulsing its proximal end to avoid reinnervation.
Presynaptic blockade of synaptic transmission with botulinurn toxin. Purified Tvoe A botulinum toxin (aenerouslv provided bv Dr. E. Schantz) was freshly diluted in mammal&t Ringer solution before use. In the SOL muscle, injections were made under direct visualization (I .5 x IO I0 gm on day 0, and I .O x 10. 1/I gm on days 6 and 12). In the FDB muscle, 1.5 x IO-I0 gm botulinum toxin was injected percutaneously on day 0, and 1.0 x IO-lo gm was injected on days 5, 12, and 19. All control animals received injections of Ringer solution at the same times. A volume of IO @I was used for all injections.
Postsynaptic blockade of ACh transmission with a-BuTx. Continuous neuromuscular blockade was produced by perfusing soleus muscles with purified u-BuTx via implantable osmotic pumps as previously described (Pestronk et al., 1980; Drachman et al., 1982; Pestronk and Drachman, 1985) . Neuromuscular blockade was initiated at day 0 by injecting I. I rg a-BuTx in PBS directly into the muscle via a fine 30 gauge needle. Blockade was then maintained by continuous perfusion of a-BuTx in PBS (0.06 &PI at 0.46 pl/hr) by means of Alzet model 2002 miniosmotic infusion pumps (Al72 Corp., Palo Alto, CA). The pumps were implanted subcutaneously into the back, and the solution was delivered directly over the belly of the SOL via tapered PE60 polyethylene tubing (Clay Adams, Parsippany, NJ) sutured in place. Control animals were injected and perfused in the same manner with similar volumes of PBS. The number of infusion pumps that could be implanted in a single cxperimcnt was limited, and we therefore elected to study the 2 time points, i.e., 4 and 6 d, which were found to be critical in our denervation and botulinum experiments. After 4 and 6 d of treatment, the muscles were removed and the loss of stable junctional AChRs was evaluated as described below (see Results).
Measurement of turnover of stable junctional AChRs. A baseline was established by removing muscles with labeled stable AChRs from the control group on day 0. Samples of 4-l 3 muscles were removed from the control and experimental groups at various times thereafter. Radioactivity bound to junctional AChRs was measured by counting the whole excised muscle in a gamma spectrometer (Micromedic Systems, Inc., Horsham, PA). The counts for each muscle were corrected for decay and then cxprcssed as a fraction ofthe mean counts of the baseline (day 0) control group for that batch of experimental mice.
In these experiments, lJ'I-a-BuTx bound to the whole SOL or FDB was used as a measure of radioactivity bound to the junctional AChRs. We conducted experiments that showed that at 6 d or more after labeling, nonspecific or extrajunctional binding was negligible. To assess the degree of nonspecific binding, we washed the muscles extensively (I8 washes over I8 hr). This removed less than I% of the bound radioactivity (unpublished results). In order to assess the degree of cxtrajunctional binding, we measured the radioactivity in the junctional region relative to extrajunctional regions. We found that 6 d after labeling more than 98% of the total muscle radioactivity was bound at the junctional regions (unpublished observations). Thus. whole muscle radioactivity can be used as an accurate measure of junctional radioactivity.
Analvsis of data. The data for each muscle (SOL or FDB) at each time point were pooled, means and SEM werc'calculated, and in the experiments with sufficient numbers oftime points, plotted on a semilog graph by the least-squares method. Data for groups of muscles were compared by the Student's 2-tailed I test.
Results
The results of this study show that treatment of the mouse SOL and FDB muscles with botulinum toxin produced a significant denervation-like acceleration of degradation of labeled stable junctional AChRs, although the onset of this effect was delayed compared with that of surgical denervation. Postsynaptic blockade with cu-BuTx, which blocks both quanta1 and nonquantal ACh transmission, produced an effect that was quantitatively equivalent to that of denervation, with an identical time course.
Presynaptic blockade of neuromuscular transmission with botulinum toxin Figure 1 shows the degradation curves for stable junctional receptors of the SOL muscle. In the control muscles, bound radioactivity was lost with a half-life of approximately I I.5 d. Within 4 d after denervation, there was a significantly greater loss ofjunctional AChRs compared with the controls (p < 0.0 l), and an increase in the rate of degradation with a half-life of 3.6 d. Following treatment with botulinum toxin, the loss ofAChRs first became significantly different from controls at 6 d (i.e., 2 d later than in the denervated group; p < 0.01). The rate of degradation increased, after botulinum treatment, to a half-life of 3.6 d. However, at the 6 d time point, the loss of labeled junctional AChRs in botulinum-treated muscles was not as great as that of the dencrvated muscles at 6 d (p < 0.01). Figure 2 shows the degradation curves for stable junctional receptors of the FDB muscle. In the control muscles, radioactivity was lost with a half-life of 16.2 d. This rate of degradation was consistently slower than that of the junctional AChRs of the SOL muscle measured here and of the reported rate for the sternomastoid muscles (Loring and Salpeter, 1980; Salpeter et al., 1986; Ramsay et al., 1988) . Following denervation, there was a trend toward more rapid degradation of AChRs by day 16, but the difference between dencrvatcd and control muscles first became statistically significant at day 20 0, < 0.001). The difference between control and denervated muscles was significant at day 4 @ < 0.01); for botulinurn-treated muscles, the difference first became significant at day 6 @ < 0.01).
treated muscles also showed a greater loss of labeled junctional AChRs, which first reached statistical significance later, at day 29 (p < 0.01).
As noted above, the accelerated turnover of AChRs began earlier after denervation than after botulinum treatment; in the SOL muscle, the loss of stable junctional AChRs was significantly greater at 4 and 6 d (p < 0.01).
Postsynaptic blockade of ACh transmission with oc-BuTx
In order to compare the effects of postsynaptic blockade of ACh transmission with those of denervation, we measured junctional AChRs of SOL muscles at 4 and 6 d after the beginning of oc-BuTx treatment and denervation. Table 1 shows that both procedures produced a highly significant loss ofjunctional AChRs at 4 and 6 d, as compared with controls (p < 0.01). Most im- portant, the effects of ol-BuTx treatment did not differ from those of denervation at either time point (p > 0.1).
Discussion
The present investigation was designed to examine the role of neuromuscular synaptic transmission in the maintenance of stability of junctional AChRs. Treatment with botulinum toxin, which blocks neuromuscular transmission presynaptically, and oc-BuTx, which acts postsynaptically, resulted in "destabilization" of preexisting AChRs at neuromuscular junctions, similar to the effect of denervation. We first compared the effects of botulinum treatment and denervation in two muscles, the SOL and the FDB. The normal rates of degradation of junctional AChRs and the time course of denervation-induced destabilization are consistently different in these 2 muscles. In both muscles, botulinum toxin treatment resulted in an unequivocal denervation-like acceleration of the turnover ofjunctional AChRs. However, in both muscles, the onset of the effect of botulinum began later than that of denervation. By contrast, postsynaptic blockade using c+BuTx quantitatively reproduced the effects of denervation on the destabilization of junctional AChRs, with an identical time course. The interpretation of these results depends on an understanding of the actions of the 2 neurotoxins used. Botulinum toxin is a specific presynaptic inhibitor of the quanta1 release of ACh (both impulse-dependent and spontaneous) from cholinergic nerves (Brooks, 1956; Thesleff, 1960; Kao et al., 1976; Simpson, 1981; Stanley and Drachman, 1983b) . It does not block the nonquantal release of ACh (Stanley and Drachman, 1983b) and has no other known actions on nerves or muscles. In particular, it does not produce structural damage (Thesleff, 1960) nor does it interfere with axonal transport (Pestronk et al., 1976) . In contrast, the action of a-BuTx is postsynaptic; numerous studies have demonstrated the specificity of action of a-BuTx in blocking the ligand-binding sites of nicotinic junctional AChRs (Changeux et al., 1970; Miledi and Potter, 1971; Lee, 1972) . or-BuTx is therefore strategically located to interfere with both quanta1 and nonquantal ACh transmission, in contrast to the quanta1 blockade produced by botulinum toxin. Although the binding of cu-BuTx to AChRs is virtually irreversible, the rapid synthesis and insertion of new AChRs at neuromuscular junctions (Ramsay et al., 1988) requires that or-BuTx be applied continuously to maintain persistent blockade of ACh transmission. Prolonged application of cu-BuTx by the perfusion method used here does not damage neuromuscular junctions morphologically or interfere with fast axonal transport (Drachman et al., 1982) . By virtue of its specificity, it is highly improbable that c+BuTx could interfere with the transport, delivery, or action of hypothetical "trophic" agents other than ACh.
The only known common denominator of action of botulinum toxin and oc-BuTx is interference with ACh transmission. Therefore, the most straightforward interpretation of our findings is that blockade of ACh transmission is responsible for the denervation-like destabilization of junctional AChRs. This suggests that neuromuscular transmission and its consequences (which include muscle contraction) play a major, if not exclusive, role in mediating the motor nerve's effect on stability of junctional AChRs.
The delayed onset of increased AChR turnover after botulinum treatment, as compared with denervation or a-BuTx treatment, was a consistent finding in our experiments. This cannot be attributed to a delay in the cholinergic blocking action of botulinum toxin since complete paralysis and nearly complete cessation of miniature endplate potentials occur within a few hours after injection of botulinum toxin (Kao et al., 1976; Pestronk et al., 1976 ). An alternative possibility is that the failure of botulinum toxin to block the spontaneous nonquantal release of ACh (Stanley and Drachman, 1983b) may account for the difference between its effects and those ofdenervation or oc-BuTx treatment on the destabilization of junctional AChRs. This is consistent with previous observations that nonquantal ACh transmission has a significant partial influence in regulating certain other properties of muscles (Mathers and Thesleff, 1978; Drachman et al., 1982) .
The mechanism by which ACh transmission influences the stability of junctional AChRs is not yet known. Clearly, the effects of ACh cannot be exerted directly on the AChRs, whose turnover is being followed in these experiments, since the Yc+BuTx used as a label itself blocks the ligand-binding sites of these AChRs. However, ACh transmission acting on nonblocked AChRs at the same junctions presumably is responsible for mediating a stabilizing effect. Although the differences between stable and destabilized AChRs have as yet been defined only in terms of their turnover times, this undoubtedly reflects some biochemical or structural differences between them. Possible differences include covalent modifications of the AChR molecules (for example, by phosphorylation, acylation, or methylation) (reviewed by Salpeter and Loring, 1985) attachment ofAChRs to cytoskeletal elements (Bloch and Hall, 1983; Froehner, 1986) , or alterations in the surrounding microenvironment of the synaptic membrane (McMahan et al., 1984) .
Perhaps the most important implication of the present work is its possible relation to synaptic memory processes. Previous studies of synaptic memory have focused for the most part on presynaptic mechanisms that modify neurotransmission (Kande1 et al., 1987) . By contrast, stabilization of AChRs constitutes a long-term modification of the neuromuscular junction at a postsynaptic level. AChR stabilization takes place over a much more extended time scale than the phenomenon of receptor "desensitization," which has previously been proposed as a form of short-term postsynaptic memory (Changeux et al., 1984 (Changeux et al., ,1987 . Thus, AChR stabilization represents a model of long-term postsynaptic "memory," albeit at a peripheral synapse between motor nerve and skeletal muscle cells. The present results demonstrate that neurotransmission plays a key role in mediating this process. We suggest that similar mechanisms of transmitterdriven receptor stabiization may be involved in memory processes in the CNS as well.
